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Perspective
I
diopathic pulmonary ﬁbrosis (IPF) 
is a disease of unknown aetiology 
and uncertain pathogenesis, 
and there are no effective therapies. 
IPF, also known as usual interstitial 
pneumonia and cryptogenic ﬁbrosing 
alveolitis, is a chronic progressive 
disease in which excessive deposition of 
extracellular matrix leads to irreversible 
scarring of interstitial lung tissue with 
consequent reduction in gas diffusion 
and loss of lung volumes. This is a 
devastating disease with an average 
survival of less than three years from 
the time of diagnosis [1]. There is 
therefore a pressing need to understand 
more about the underlying cellular, 
molecular, and genetic mechanisms 
in order to more effectively monitor 
the disease, follow its progression, and 
most importantly to develop effective 
treatments. Understanding the ﬁbrotic 
process also has implications for 
other chronic ﬁbrotic diseases, such 
as cirrhosis, and for ﬁbrosis of small 
airways, which is the main lesion of 
chronic obstructive pulmonary disease.
Pathology of IPF
Pulmonary ﬁbrosis results from injury to 
alveolar epithelial cells and represents a 
repair process that is inappropriate. The 
cause of the original injury is unknown, 
and there may be several causal 
mechanisms and pathways that all 
end up with excessive and progressive 
scarring of the lung. A major problem 
in clinical research in this disease is the 
late presentation of clinical symptoms, 
as shortness of breath on exertion only 
becomes apparent when less than 50% 
of lung capacity remains. By this stage 
the disease is essentially untreatable and 
has a poor prognosis.
The disease is patchy, and the 
characteristic histological feature of 
IPF is the presence of ﬁbroblastic foci 
with areas of ﬁbrosis. There is usually 
a low-grade inﬂammation, but the role 
of inﬂammation is controversial as 
there are often few inﬂammatory cells 
and there is no signiﬁcant therapeutic 
beneﬁt of anti-inﬂammatory 
treatments, such as corticosteroids and 
azathioprine. The absence of response 
to anti-inﬂammatory treatment 
suggests that ﬁbrosis may develop 
as the consequence of an abnormal 
wound healing response to some type 
of chronic alveolar epithelial injury 
[2]. However, inﬂammation may play a 
more important role in the early stages 
of disease and may then disappear. 
The trigger that initiates the alveolar 
injury in IPF is unknown, but there 
is increasing recognition that there 
may be many causes and that many 
different interacting pathways may be 
activated to produce the abnormal 
healing response, based in part on 
genetic susceptibility [3]. The genes 
that determine susceptibility to IPF have 
not yet been identiﬁed, but there is 
particular interest in genes that regulate 
tissue repair [4]. Important clues may 
be provided by familial pulmonary 
ﬁbrosis, which is a rare dominant trait 
with incomplete penetrance. 
The Challenge of Identifying 
Possible Biomarkers
In view of the complexity of IPF it 
has been difﬁcult to identify useful 
biomarkers in bronchoalveolar lavage 
or blood, particularly ones that might 
be clinically useful in differentiating IPF 
from other pulmonary ﬁbrotic diseases 
such as hypersensitivity pneumonitis 
(HP) and non-speciﬁc interstitial 
pneumonia (NSIP). Gene microarray 
of lung biopsies from patients with IPF 
reveals a distinct pattern, with increased 
expression of tissue remodelling, 
epithelial, and myoﬁbroblast genes, 
whereas HP shows a greater expression 
of inﬂammatory and immune genes 
[5]. Matrix metalloproteinases 
(MMPs), especially MMP7, also show 
increased gene expression in IPF 
lungs [6]. Interestingly, NSIP, which 
is often difﬁcult to differentiate from 
IPF and HP, shows a different pattern 
of gene expression, although some 
cases resemble the proﬁle of either 
IPF or HP. These studies imply that 
different patterns of biomarkers might 
distinguish these different types of 
pulmonary ﬁbrosis, and they suggest 
that blood markers could be identiﬁed 
for this purpose. 
There has been an extensive search 
for such biomarkers of IPF, with interest 
in the increased plasma concentrations 
of surfactant proteins and the 
ﬁbrogenic cytokine osteopontin [7,8]. 
In a new study published in this issue 
of PLoS Medicine, Naftali Kaminski and 
colleagues assayed 49 plasma proteins 
in a relatively large number of patients 
with IPF (74 patients with IPF and 53 
healthy controls) and showed that ﬁve 
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Linked Research Article
This Perspective discusses the 
following new study published in PLoS 
Medicine:
Rosas IO, Richards TJ, Konishi K, Zhang 
Y, Gibson K, et al. (2008) MMP1 and 
MMP7 as potential peripheral blood 
biomarkers in idiopathic pulmonary 
ﬁbrosis. PLoS Med 5(4): e93. doi:10.1371/
journal.pmed.0050093
Naftali Kaminski and colleagues ﬁnd 
increased levels of speciﬁc proteins in the 
bloodstream of individuals with idiopathic 
pulmonary ﬁbrosis, and suggest that 
these proteins may ultimately provide a 
biomarker for the disease.
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of these proteins distinguished IPF from 
controls [9]. The concentrations of two 
of these proteins, MMP1 (collagenase) 
and MMP7 (matrilysin), were also raised 
in lung tissue and bronchoalveolar 
lavage of patients with IPF. 
Furthermore, MMP1 and MMP7 plasma 
concentrations were greater in patients 
with IPF than in patients with other 
chronic ﬁbrotic lung diseases, including 
chronic obstructive pulmonary disease, 
sarcoidosis, and HP. Patients with NISP 
were not included in this study, but it 
is likely that such patients would show 
similar changes in MMP1 and MMP7 
to those seen in patients with IPF, as 
increased expression of MMP1 and 
MMP7 has previously been reported in 
lung tissue and bronchoalveolar lavage 
ﬂuid of patients with both IPF and 
NSIP [10,11]. Elevated plasma MMP7 
was found in patients with IPF with 
asymptomatic disease, albeit at lower 
concentrations than in symptomatic 
disease, and correlated with reduced 
gas diffusion and lung volumes. These 
ﬁndings suggest that MMP7 levels may 
be used as an early marker of disease 
and may be useful in monitoring 
disease progression. 
Kaminski and colleagues’ ﬁndings 
have biological plausibility, as abnormal 
expression of MMPs have previously 
been reported in lungs of patients with 
IPF [10,12], and this family of more 
than 20 enzymes regulates the turnover 
of all extracellular matrix proteins. 
MMP1 is not normally expressed and 
degrades ﬁbrillar collagen, whereas 
MMP7 degrades other extracellular 
matrix proteins and is involved in 
tissue remodelling. These MMPs may 
be produced by alveolar epithelial cells 
in response to injury, or perhaps to 
inﬂammatory mediators and oxidative 
stress in parallel with ﬁbrogenic 
mediators such as transforming growth 
factor-β (TGF-β) (Figure 1). Whether 
they play a role in counteracting ﬁbrosis 
or may contribute to pathogenesis is 
unclear, but it is likely that they are 
a signature of tissue remodelling. 
MMPs may generate neutrophil 
chemotactic peptides from extracellular 
matrix proteins [13], which may link 
neutrophilic inﬂammation to IPF, 
and this may further stimulate ﬁbrosis 
through the release of reactive oxygen 
species and TGF-β. However, in mice 
with targeted disruption of the MMP7 
gene there is a reduction in the ﬁbrotic 
response to bleomycin, suggesting that 
it may have a proﬁbrotic role [6].
Moving Towards Clinical 
Application
What is the clinical relevance of these 
ﬁndings? Elevation of plasma MMP1 and 
MMP7 may help to conﬁrm a diagnosis 
of IPF and probably NSIP, and help 
to distinguish these diseases from HP, 
sarcoidosis, and perhaps other ﬁbrotic 
lung diseases. However, a normal 
individual value does not exclude these 
diagnoses, as there is considerable 
overlap between levels of these MMPs in 
healthy people and patients with other 
chronic lung diseases. However, the 
plasma concentrations of MMP7 may be 
useful in following disease progression 
and even in facilitating early diagnosis. 
This marker is unlikely to be useful in 
screening for IPF, as it is an uncommon 
disease. It is not yet known whether 
plasma MMP1 and MMP7 are useful 
indicators of rapid disease progression 
or may be used for early detection of 
acute exacerbations. What this study 
tells us about disease mechanisms and 
future therapy is uncertain, as the roles 
of MMPs in the pathogenesis of IPF are 
far from clear.  
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Figure 1. Mechanisms of IPF 
Injury of alveolar epithelial cells releases ﬁbrogenic mediators, such as TGF-β, which stimulate 
myoﬁbroblasts to produce extracellular matrix proteins. Matrix metalloproteinases MMP1 and MMP7 
are also produced and may reﬂect tissue remodelling or contribute to ﬁbrosis through recruitment 
of neutrophils, which release reactive oxygen species and TGF-β. Increased plasma concentrations 
of MMPs may therefore reﬂect increased extracellular matrix turnover and disease activity.